Zobrazeno 1 - 5
of 5
pro vyhledávání: '"59"'
Autor:
Rob E. Aarnoutse, Johannes H. Proost, Marieke G G Sturkenboom, Wiel C M de Lange, Jos G. W. Kosterink, Jan-Willem C. Alffenaar, Arthur de Jager, Richard van Altena, Tjip S. van der Werf, Leonie W. Mulder
Publikováno v:
Antimicrobial Agents and Chemotherapy, 59(8), 4907-4913. AMER SOC MICROBIOLOGY
Antimicrobial Agents and Chemotherapy, 59, 8, pp. 4907-13
Antimicrobial Agents and Chemotherapy, 59, 4907-13
Antimicrobial Agents and Chemotherapy, 59, 8, pp. 4907-13
Antimicrobial Agents and Chemotherapy, 59, 4907-13
Rifampin, together with isoniazid, has been the backbone of the current first-line treatment of tuberculosis (TB). The ratio of the area under the concentration-time curve from 0 to 24 h (AUC 0–24 ) to the MIC is the best predictive pharmacokinetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9da7b315295cfca04615bc5e48941849
https://europepmc.org/articles/PMC4505200/
https://europepmc.org/articles/PMC4505200/
Autor:
Michael A. Lyons
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
Pretomanid is a nitroimidazole antibiotic in late-phase clinical testing as a component of several novel antituberculosis (anti-TB) regimens. A population pharmacokinetic model for pretomanid was constructed using a Bayesian analysis of data from two
Autor:
Uwe Hahn, Michael S. Roberts, Jason A. Roberts, Fekade B. Sime, Sandra L. Peake, Jeffrey Lipman, Morgyn S. Warner, Ing Soo Tiong
Changes in the pharmacokinetics of piperacillin in febrile neutropenic patients have been reported to result in suboptimal exposures. This study aimed to develop a population pharmacokinetic model for piperacillin and perform dosing simulation to des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72531b13416062580d3e9306a7dcc0e7
https://europepmc.org/articles/PMC5655099/
https://europepmc.org/articles/PMC5655099/
Autor:
Birgitte Brock, Kristina Öbrink-Hansen, Eskild Petersen, Mads Kreilgaard, Marianne Kragh Thomsen, Tore Forsingdal Hardlei, Søren Jensen-Fangel
Publikováno v:
Öbrink-Hansen, K, Hardlei, T F, Brock, B, Jensen-Fangel, S, Kragh Thomsen, M, Petersen, E & Kreilgaard, M 2015, ' Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia ', Antimicrobial Agents and Chemotherapy, vol. 59, no. 4, pp. 2398-404 . https://doi.org/10.1128/AAC.04659-14
When antimicrobials are used empirically, pathogen MICs equal to clinical breakpoints or epidemiological cutoff values must be considered. This is to ensure that the most resistant pathogen subpopulation is appropriately targeted to prevent emergence
Autor:
Sang-Goo Shin, Ki-Won Kim, Kwang-Hee Shin, Young Hwan Hwang, Curie Ahn, In-Jin Jang, Kook Hwan Oh, Min-Gul Kim, Yun Kyu Oh, Han Ro, Kyung Sang Yu
Publikováno v:
Antimicrobial Agents and Chemotherapy. 55:2523-2527
The pharmacokinetics (PK) of ceftazidime after intravenous (i.v.) administration during automated peritoneal dialysis (APD) and their dependence on peritoneal membrane transport are the targets of the present study. Eleven patients receiving a single